Cytokinetics Inc.’s(CYTK) share price has moved into oversold territory with a stochastic value of 5.94. The Zacks Consensus Estimate on the company’s full-year earnings has climbed 40 cents over the past 3 months to 36 cents per share. Cytokinetics is a Zacks #1 Rank (“Strong Buy”) company.
“CYTK” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Uncategorized